Connect with us

Cannabis News

New Farm Bill Released By GOP Committee Chair Aims To Reduce Hemp Industry ‘Regulatory Burdens’

Published

3 months ago

on

A top House committee chairman has introduced the latest version of a large-scale agriculture bill with provisions that his office says will reduce “regulatory burdens on industrial hemp producers.”

The proposed 2026 Farm Bill released Friday by House Agriculture Committee Chairman Glenn Thompson (R-PA) would maintain the industrial hemp program as the cannabinoid industry waits for the recriminalization of consumable cannabinoid products under legislation signed into law by President Donald Trump last year.

But for farmers who grow hemp for industrial purposes, such as fiber and grain, the latest version of the Farm Bill is being touted as a source of industry relief, with policies that allow the US Department of Agriculture (USDA), as well as states and tribes, to reduce or eliminate “testing requirements and background checks for producers.”

Those provisions are modeled after the Industrial Hemp Standalone Act, bipartisan legislation introduced in the 118th Congress aimed at strengthening the hemp market after the crop and its derivatives were federally legalized in 2018 during Trump’s first term.

Under the new 2026 Farm Bill, the USDA would also be mandated to “establish a process by which hemp testing laboratories can be accredited,” a section-by-section summary says. Currently, only Drug Enforcement Administration (DEA)-accredited laboratories can test hemp yields for compliance purposes, which has created a bottleneck that has historically limited resources.

“A new farm bill is long overdue, and the Farm, Food and National Security Act of 2026 is an important step forward in providing certainty to our farmers, ranchers and rural communities,” Thompson said of the sweeping legislation in a press release Friday.

“This bill offers modern policies for modern challenges and builds on years of listening to the needs of farmers, ranchers and rural Americans,” he said. he said. “The farm bill affects our entire country, whether you live on a farm or not, and I look forward to my colleagues in Congress working together to push this critical legislation through the finish line.”

His panel will begin examining the bill on February 23.

Although the text of the legislation has only just been released to the public, the Democratic leadership has already argued with the draft proposal.

“A review of the text of the legislation is underway,” said Rep. Angie Craig (D-MN), a member of the committee. “As far as I know, the Republican farm bill doesn’t meet the moment before farmers and workers.”

“Farmers need Congress to act quickly to end inflationary tariffs, stabilize trade relations, expand domestic market options like year-round E15, and help lower input costs. The Republican majority instead chose to ignore Democratic priorities and push through a farm bill with poison pills if nothing else complicates their options.” he said. “I strongly urge my Republican colleagues to put aside the political brass and work with House Democrats on a bipartisan bill that addresses the real issues facing farmers right now, before it’s too late.”

Again, regardless of how the proposed revisions to industrial hemp policy play out, there is a more pressing concern for the primary economic driver of the cannabis market—the farmers, manufacturers, and processors of cannabinoids in consumable products like CBD—in this latest Farm Bill.

The spending legislation signed by the president would once again ban cannabinoid products containing trace amounts of THC, which advocates say would upend an already struggling market.

Since 2018, cannabis products have been considered legal hemp if they contain less than 0.3 percent delta-9 THC by dry weight.

However, the law, which will take effect in November, specifies that the weight would be applied to total THC — including delta-8 and other isomers. Also, “as tetrahydrocannabinol (or any other marketed cannabinoid) with similar effects in humans or animals (as determined by the Secretary of Health and Human Services).”

The new definition of legal hemp would also prohibit “any hemp-derived cannabinoid intermediate product marketed or sold as an end product or directly to an end consumer for personal or household use,” as well as products containing cannabinoids that are synthesized or manufactured outside of the cannabis plant or that cannot be produced naturally by the plant.

Legal hemp products would be limited to 0.4 milligrams total THC per container or any other cannabinoids with similar effects.

A bill called the Hemp Enforcement, Modernization and Protection (HEMP) Act is a potential alternative to the outright THC ban included in the spending bill signed by Trump. in the affirmative allowing the sale of consumable hemp products to adults over 21 years of age. This includes edibles, beverages and breathable items.

If the legislation were to be enacted, there would be several regulatory restrictions on the market. For example, packaging should not appeal to young people and should be fake. It should also list all the cannabinoids present and include a QR code that links to a certificate of analysis.

Manufacturers of hemp products would be prohibited from adding substances such as alcohol, caffeine, tobacco, nicotine, melatonin or others “that may interact with cannabinoids or enhance or modify their effects.”

There would also be manufacturing and testing requirements, and hemp companies would have to register their facilities.

Additionally, there are provisions mandating the establishment of a total cap on cannabinoids in hemp products. The US Department of Health and Human Services (HHS) would be responsible for proposing the cannabinoid limits within 60 days of their enactment.

In the meantime, the liquor dealers got together recently Encourage Congress to delay passage of the law Trump signed to federally recriminalize THC beverages and other hemp-derived products.

The coalition calls on the members of parliament to approve the legislation they have just presented Hemp Plantation Provision Lawthat would give the hemp industry two more years before a federal ban on THC products takes effect, which stakeholders hope will better position them to negotiate a broader regulatory compromise.

House Oversight and Government Reform Committee Chairman James Comer (R-KY), who is sponsoring the proposal, appeared at a news conference last month. farmers concerned about the impact of the federal hemp ban in their businesses.

what’s the point Four out of five marijuana users say they oppose the recriminalization of THC hemp products According to the spending bill Trump signed in November. However, it should be noted that this survey was conducted a few weeks before the cannabis rescheduling order and measures to protect access to full-spectrum CBD.

Meanwhile, it would make way for a recently introduced bill in the Republican-led Congress stop implementing the hemp ban under established credit legislation.

—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters By pledging at least $25 per month, you’ll get access to our interactive maps, charts and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

Hemp companies and industry groups have warned about the potential ramifications of the ban, but despite states in support of cannabis rights and a social media post extolling the benefits of CBD, Trump signed the underlying spending measure into law without endorsing the hemp provisions.

GOP political operative Roger Stone recently said it was Trump effectively “forced” Republican lawmakers to sign the spending bill with language to ban hemp THC.

However, a White House spokesman said before signing the bill Trump was particularly supportive of the ban’s language.

The Democratic governor of Kentucky said that the hemp industry is an “important” part of the economy that deserves to be regulated at the state level—instead of being banned federally, as Congress has done—.

Additionally, a leading veterans organization is alerting Congressional leaders to the recently passed blanket ban on consumable hemp products. could inadvertently “close the door” on critical inquiry.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Related Topics:
Continue Reading

Cannabis News

Cannabis operators report mixed results as rescheduling reshapes the financial outlook

Published

8 hours ago

on

May 14, 2026

By

The rescheduling came mid-quarter and rewrote the tax math for each medical sales operator, but the underlying revenue picture remained uneven in early 2026, with acquisitions driven at one end of the scale and continued top-line compression at the other.

Vireo Growth: Back on $106 million deal
Vireo Growth Inc. reported Q1 GAAP revenue of $106.2 million, up 333.5% year-over-year, driven almost entirely by recent acquisitions rather than organic growth. The company completed the Schwazze acquisition in March, adding 45 dispensaries and two manufacturing facilities in Colorado and New Mexico. At the end of the quarter, it closed Eaze and Hawthorne Gardening, FLUENT Corp. announced an acquisition agreement and executed a California dispensary joint venture with Glass House Brands. Treating all acquisitions as closed on January 1, 2025 on a pro forma basis, revenue was $210.2 million and adjusted EBITDA was $42.2 million. The company ended the quarter with $137.8 million in cash.

John Mazarakis, CEO of Vireo, said: “Performance in the first quarter met our expectations and we are excited to welcome Schwazze, Eaze and Hawthorne to Vireo. We are focused on integration and optimization across the platform, while remaining opportunistic regarding growth opportunities associated with further acquisitions.”

Cresco Labs: $151 million, 280E relief and Texas license
Cresco Labs reported Q1 revenue of $151 million, down from $165.8 million in Q1 2025. Adjusted gross margin was 50.7% and adjusted EBITDA margin of $33 million was 21.7%. Cash at the end of the quarter was $67 million against a $310 million secured term loan. The company was conditionally granted a Texas Compassionate Use Program license after the quarter ended and opened two new dispensaries in Ohio.

Management said, “Moving the state’s legal medical cannabis from Schedule I to Schedule III is the most impactful reform this industry has seen, and it validates the work we’ve been executing for years. We’ve built the operational foundation and balance sheet discipline to reap the immediate benefits of rescheduling, and position Cresco to take advantage of the broader path to normalization.”

Jushi Holdings: 4% growth, 460 basis point margin expansion
Jushi Holdings reported first-quarter revenue of $66.4 million, up 4% year-over-year, with gross profit margin up 460 basis points to 45%. Adjusted EBITDA was $11.4 million, up 17.2%. The margin improvement was driven by higher production volumes in Ohio, Massachusetts and Pennsylvania and the performance of grower processors. Jushi brand products accounted for 58% of retail revenue in vertical markets. The company refinanced $132.3 million in debt during the quarter, providing $160 million in new debt through 2029.

Jim Cacioppo, president and CEO, said: “The recent scheduling of state-licensed medical marijuana for Schedule III is an important milestone for the industry, eliminating 280E tax limitations for medical operations and supporting a more favorable long-term operating environment.” Medical sales accounted for about 60% of Jushi’s 2025 revenue, making this material relief.

iAnthus Capital: Revenue falls to $33.5 million
iAnthus Capital reported first-quarter revenue of $33.5 million, down $4.6 million from 2025’s first quarter. Gross margin was 47.5%, up 477 basis points from the 2025 quarter. The company did not provide a management comment in the press release.

Country farms: international export record, fourth consecutive quarter of net income
Village Farms International reported first quarter consolidated net sales of $50.2 million, up 27% year-over-year, with net income of $2.9 million and adjusted EBITDA of $9.9 million, up 118% year-over-year. International export sales increased 171% to a record $14.6 million, driven by demand for EU-GMP compliant products in Germany. Pure Sunfarms had the top Canadian market share in dried flowers for the 15th consecutive month. The company started planting the first half of its Delta 2 greenhouse expansion and expects its Phase II facility in the Netherlands to reach full capacity by the end of 2026, which would quadruple Dutch production.

Michael DeGiglio, President and CEO, said: “Our first quarter results reflect a strong start to the year and continued momentum in our largest markets, with adjusted EBITDA growth of 118% year-over-year, significantly outpacing revenue growth of 27%, driven by our international business and continued leadership in Canada.

Cronos Group: Record revenue, $822 million in cash
Cronos Group reported Q1 net income of $45.2 million, up 40% year-over-year and a record quarter, with net income of $15.7 million and adjusted EBITDA of $5.1 million. Israel led growth PEACE NATURALS grew 53% for ninth consecutive record quarter. In Canada, the Spinach brand took first place in vapes with a 9.8% share of the national market, and maintained its top spot in edibles at 20.8%. The company ended the quarter with $821.9 million in cash and authorized a new $50 million stock repurchase program. The deadline to close the acquisition of CanAdelaar, one of the ten licensed growers in the Dutch Controlled Cannabis Supply Chain Experiment, has been extended to September 9, 2026 to allow time for regulatory approvals.

Mike Gorenstein, chairman, president and CEO, said, “Cronos achieved net earnings and gross profit in the first quarter as we continue to execute against our unlimited product strategy and the additional supply from Cronos GrowCo’s expansion fuels the next phase of our growth.”

Org chart: Revenue down 9%, Sanity Group acquisition closes after quarter
Organigram Global reported fiscal second quarter net income of $59.8 million, down 9% year-over-year, with adjusted EBITDA of $0.9 million, down 82%. Lower vape and pre-infusion sales drove the decline, along with a $5.8 billion dent in the U.S. hemp business. The company achieved a record quarterly harvest of over 32,000kg at its Moncton facility, up 56% year-on-year, and launched 10 SKUs in Australia targeting over 4,000 pharmacies. At the end of the quarter, Organigram acquired Sanity Group, one of Germany’s leading cannabis companies, and updated its 2026 guidance to net revenue of more than $350 million.

James Yamanaka, CEO, said: “Q2 reflected our poor performance in vaporizers and temporary challenges in pre-infusion production, compounded by slower industry growth. We have acted quickly to address these issues, and the operational changes and product improvements we have implemented are already beginning to stabilize performance.”

Greg Guyatt, Chief Financial Officer, said: “The financial impact of the competitive and operational challenges encountered earlier in fiscal 2026 is believed to have materialized in the first half of the year, and we are now beginning to stabilize performance. We expect to resume a trajectory of margin expansion and improved profitability during the second half of the year, supported by positive revenue and international sales growth. The Sanity Group.”

Continue Reading

Cannabis News

Medical Marijuana Helps Pain Patients Reduce Use Of Opioids, New Study Shows

Published

9 hours ago

on

May 14, 2026

By

As opioids continue to cause overdose deaths, a new study suggests that making medical cannabis available and affordable could help patients reduce their use of prescription painkillers.

“Although cannabis has historically been characterized as a potential ‘gateway drug,’ it may also serve as a harm reduction tool for some patients seeking to reduce their reliance on higher-risk opioid medications,” researchers at the University of Pennsylvania Perelman School of Medicine found.

The study, a prospective observational trial at the Hospital of the University of Pennsylvania, followed 29 adults over five months. All had been living with chronic pain for years—an average of 11 years—and were already taking opioid medications, but struggled to taper off of them despite other treatments.

The study is unique in its focus on cost as a factor in access to medical marijuana, with the researchers describing their work as “the first prospective observational study evaluating medical cannabis as an alternative to opioids in a setting where cost was removed as a major barrier.”

Participants were recruited from a university outpatient chronic pain clinic and then completed monthly pain assessments using the Numeric Pain Rating Scale (NRS). The researchers measured daily opioid use, measured in milligrams of morphine equivalents (MME).

“Seven patients (24%) were able to completely discontinue opioid therapy at the end of the study, five of whom did so by the second month. Pain levels also decreased over time,” the authors wrote.

Notably, “there was a statistically significant reduction in mean pain scores experienced over the five-month study period,” says the paper published in the Cureus Journal of Medical Science.

“There was also a reduction in average opioid consumption of about 32 MME per day, which remained the same throughout the follow-up. In addition, seven patients were able to completely discontinue opioid therapy during the study.”

“Mean daily opioid consumption decreased from 46.8 MME/day at baseline to 16.2 MME/day at one month and remained low during the five-month follow-up period,” the researchers found.

What set the new study apart was not just the inclusion of medical cannabis, but the deliberate removal of cost as a barrier. Participants “consistently identified cost as a major barrier to initiating medical cannabis” before enrolling in the study, the document says.

Noting the novelty of the study, they added their hypothesis: “Improving access to medical cannabis will allow a subset of patients, especially those with a high cost barrier, to reduce or discontinue opioid use while maintaining adequate pain control.”

“These results suggest that medical cannabis may be a useful adjunctive therapy to reduce opioid use, relieve chronic pain, and improve health-related quality of life,” they concluded.

“The findings of this study add to the body of literature supporting the safety profile and potential therapeutic role of cannabis.”

The studies the authors are cautious in their conclusions, warning of limitations and the need for further research. “The sample size was small and derived from a single clinical site, and there was no control group.” And because “patients self-titrate cannabis products, leading to variability in dosage and frequency of use,” the findings are not standardized.

But the authors concluded that “when used under appropriate medical supervision, medical cannabis may be an effective adjunctive strategy to reduce opioid use among patients receiving long-term opioid therapy.”

This study follows a Recent research shows that using medical marijuana helps people reduce their use of other drugs, including opioids.sleep aids and antidepressants. They also experience fewer negative side effects after switching from prescription drugs to cannabis, according to a study involving more than 3,500 patients.

It also comes from behind President Donald Trump says marijuana ‘can make people feel a lot better’ and serves as a “substitute for addictive and potentially lethal opioids.”

Last month, the Trump administration announced it moving forward with federal reclassification of marijuana medicinal cannabis is classified under Schedule I to III of the Controlled Substances Act.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Livermore Falls debates cannabis licensing fees

Published

1 day ago

on

May 13, 2026

By











Existing medical cannabis licensing fees will be temporarily applied to recreational marijuana businesses, the Select Committee decided on May 5. Board members agreed 4-1 to the temporary change, as long as officials say the fees are higher than necessary and accurately reflect the town’s oversight costs.

Bryce Cobb, Livermore Falls’ code enforcement officer, plumbing inspector, health officer and E-911 dispatcher, said voters approved the amended cannabis ordinance on April 28. Cobb said the amended ordinance allows recreational marijuana businesses and the next step was to establish a fee schedule. Recreational cannabis businesses operating in town would require local licensing approval under the ordinance.

Asked if he had fee schedules from other towns to compare, Cobb said he did not. Additionally, the town’s fee schedule specifically mentions medicinal cannabis.

“So it could be medical and adult use,” Cobb said when discussing whether the existing fee structure could apply to recreational businesses.

Read more at Sun Magazine










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media